Search
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic IndexProducts: TAFINLAR®75 MG CÁPSULAS DURAS, TAFINLAR® 50 MG CÁPSULAS DURASFerrous fumarate
go.drugbank.com/drugs/DB14491ApprovedInvestigationalUsed in treatment of iron deficiency anemia.
Mixtures: WOMEN`S MULTIVITE WITH EVENING PRIMROSE OIL,ROYAL JELLY & KOREAN GINSENG, Se-Vate 21/7Synonyms: Iron(2+) fumarateAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … [A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells. … [A224044, L20974] It is set to enter phase 3 clinical trials.
Lactic acid
go.drugbank.com/drugs/DB04398ApprovedInvestigationalVet approvedIt is produced by fermentation of a sugar source, such as corn or beets, and then, by neutralizing the resulting lactic acid to create a compound having the formula NaC3H5O3. … (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste.
Mixtures: LACTATED RINGER`S SOLUTION 500ML, (HARTMANN`S SOLUTION ) WITH 5% GLUCOSE IN 1000 ML PLASTIC CONTAINERSynonyms: 2-Hydroxypropanoic acid, 2-Hydroxypropionic acidOzenoxacin
go.drugbank.com/drugs/DB12924Approveds Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingThreonine
go.drugbank.com/drugs/DB00156ApprovedInvestigationalNutraceuticalAn essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.
Synonyms: L-2-Amino-3-hydroxybutyric acid, L-α-amino-β-hydroxybutyric acidMixtures: AMINOACIDI S BIOINDUSTRIA L.I.M., AMINOSTERIL N-HEPA 8%Azidocillin
go.drugbank.com/drugs/DB08795ExperimentalAzidocillin is a penicillin antibiotic similir to ampicillin.
Synonyms: (2S,5R,6R)-6-{[(2R)-2-azido-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, D-(−)-(α-azidobenzyl)penicillinCategories: Heterocyclic Compounds, 2-RingAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. … Alpelisib is marketed under the trade name Piqray and is available as oral tablets.
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexImelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigational[L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922] … Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.